Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $56.57M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.63M
Average 0.42M
CRBP Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $4.44M rose 7.3% year over year, ahead of the -5.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 24.6% from the prior quarter. Over 3 fiscal years it compounded at -6.6% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $9.06M (-40.5%) for the fiscal year ending Dec 2026, a slowdown from the -7.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.44M+24.6% QoQ
- Last fiscal yearDec 2025
- $15.22M-7.8% YoY
- LTMMar 2026
- $15.52M-5.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 15.22M USD
- Year-over-year change
- -7.8%
- 4-year CAGR
- -7.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.22M | -7.8% |
| FY2024 | 2024-12-31 | 16.5M | +18.6% |
| FY2023 | 2023-12-31 | 13.91M | -25.6% |
| FY2022 | 2022-12-31 | 18.7M | -8.5% |
| FY2021 | 2021-12-31 | 20.43M | — |
Selling, General & Admin vs competitors
How CRBP compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.5% is the 6th highest of 10, against a peer median of -4.4%.
- Over three fiscal years its annual growth of -6.6% compares with a peer median of -4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.37M USD | -20.9% | -4.0% | 257.2% | |
| LTM Mar 2026 | $34.83M USD | -4.4% | -11.4% | 1952.5% | |
| LTM Mar 2026 | $22.56M USD | +1.9% | +16.6% | — | |
| LTM Mar 2026 | $19.01M USD | -17.8% | -9.7% | 599.8% | |
| LTM Mar 2026 | CHF 16.11M CHF | -3.8% | -12.0% | — | |
| LTM Mar 2026 | $15.52M USD | -5.5% | -6.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $13.7M USD | +20.3% | +31.5% | — |
| LTM Mar 2026 | $13.02M USD | +27.1% | +2.6% | 2479.6% | |
| FY2025 | €11M EUR | -7.8% | -8.7% | 394.7% | |
| LTM Mar 2026 | $10.95M USD | -28.8% | +14.3% | — | |
| Peer median (excluding CRBP) | — | -4.4% | -4.0% | 599.8% | |
Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 881.71K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.64M | 1.49M | 0 | 600K | 0 |
| Gross Profit | (757.53K) | (1.49M) | 0 | (600K) | 0 |
| Gross Margin | -85.9% | — | — | — | — |
| Research & Development | 36.45M | 16.14M | 31.17M | 32.22M | 70.1M |
| Selling, General & Admin | 20.43M | 18.7M | 13.91M | 16.5M | 15.22M |
| Operating Expenses | 55.23M | 33.35M | 45.08M | 48.12M | 85.31M |
| Depreciation & Amortization | 1.64M | 1.49M | 641K | 600K | 233K |
| EBITDA | (42.17M) | (38.73M) | (40.11M) | (37.74M) | (78.3M) |
| EBITDA Margin | -4782.9% | — | — | — | — |
| Operating Income | (55.99M) | (34.84M) | (45.08M) | (48.72M) | (85.31M) |
| Operating Margin | -6350.1% | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 6.31M | 5.53M |
| Interest Expense | 1.83M | 2.13M | 2.92M | 1.87M | 0 |
| Other Income / Expenses | 10.35M | (7.51M) | 474K | 8.51M | 6.77M |
| Income Before Tax | (45.64M) | (42.35M) | (44.6M) | (40.21M) | (78.54M) |
| Pre-Tax Margin | -5176.4% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (45.55M) | (55.83M) | (44.6M) | (40.21M) | (78.54M) |
| Net Margin | -5166.4% | — | — | — | — |
| EPS (Basic) | (11.13) | (10.15) | (10.31) | (3.68) | (5.90) |
| EPS (Diluted) | (11.13) | (10.15) | (10.31) | (3.68) | (5.90) |
| Weighted Avg Shares | 4.1M | 4.17M | 4.33M | 10.92M | 13.32M |
| Weighted Avg Shares (Diluted) | 4.1M | 4.17M | 4.33M | 10.92M | 13.32M |
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
Intrinsic Alpha fair value
Locked
Current Price
$2.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.